Ibuprofen API Market Size, Analysis, Top Players, Target Audience and Forecast to 2029

The global ibuprofen API market surpassed US$ 572.9 Mn in 2019 and is set for a stable growth outlook over the course of 2019 – 2029, as per the findings of a new Future Market Insights (FMI) study. The primary factors for growth of the Ibuprofen API market include continuous demand for low-cost non-steroidal anti-inflammatory drugs (NSAID), and scale and age of manufacturing facilities.

Increasing API drug shortages and assembling task force to overcome these problems, emergence of cost-effective drug manufacturers in various countries and supply of API drugs, primarily in developing countries, are further driving ibuprofen API market growth.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11260

The pharmaceutical API industry is witnessing a substantial crunch in supply and demand of Ibuprofen API, halted production from major ibuprofen API manufactures, supply chain disruption in china further led by declining sale in India. The volatility in Ibuprofen API is due to factors such as lower number of competitors, reduced utilization ratio, lower margin level, new higher-value opportunities in complex combinations and high-grade API, pace of facility inspection by FDA, and ramping up production capacity of through mergers and consolidation.

Ibuprofen API Market by End User

Ibuprofen API Market

FMI Analyses the COVID-19 Impact on Market

FMI’s analysis suggests that the ongoing COVID-19 pandemic is having adverse impacts on market growth. Wuhan, China is the hub of API supplies. The region is the epicenter of the coronavirus outbreak, as such, it has temporarily halted its manufacturing facilities. Further, China is the prominent or the sole supplier of APIs including, penicillin and erythromycin, in the world. Manufacturers and distributors in the country are blaming logistical barriers and labor scarcity due to the COVID-19 pandemic for delay in production and transportation.

Key Takeaways of Ibuprofen API Market Study

  • Greater focus on relieving pressure of supply chain due to demand gap is being tackled by ramping up production capacity, up-scaling is the fundamental strategy outlined for meeting demand in the Ibuprofen API space.
  • Majority of the anti-inflammatory drugs are manufactured in Asia, especially in China and India. Approximately 80% of the total anti-inflammatory APIs are manufactured in India and China and most of the APIs manufactured in these countries are outsourced to other developed regions – North America and Europe.
  • High upfront cost and lower margin level in Ibuprofen API have resulted in 20-30% price spike in final drug formulations and lower sales in previous year.
  • The market for Ibuprofen API is consolidated in nature, with leading manufacturers holding around 90% of market value as 90%. Hence, growing interest of CMOs and large-scale API manufacturers are anticipated to boost the value creation of ibuprofen API market.
  • Higher volume handling by Contract Manufacturing Organizations in comparison to pharmaceutical companies and amid higher production capabilities and price advantage over pharmaceutical companies are expected to generate significant revenue pockets.
  • Expanding patient pool consuming non-controlled drugs as OTC are also responsible for the growth of in-house ibuprofen API consumption in South and East Asia.

Capacity Expansion, and Strategic Mergers & Acquisitions to Widen Regional Presence

Leading players in ibuprofen API market – SI Group, Inc., BASF SE, Hubei Biocause Phamaceutical Co., Ltd. (BIOCAUSE Inc.), IOL Chemicals, Sino-US Zibo Xinhua-Perrigo Pharmaceutical Co., Ltd., and Solara Active Pharma Sciences Limited – are focusing on business expansions by mergers, joint ventures, distribution agreements and capturing the untapped potential of the Ibuprofen API market.

  • In 2018, IOL Chemicals, the largest Indian Ibuprofen API manufacturer, expanded its production capacity to 12000 MT from previous capacity of 7500 MT. With the increased capacity, IOL Chemicals is filling the demand-supply gap that is rising due to stringent regulatory reform in China. This move can further benefit the Indian manufactures looking to strengthen their foothold in Ibuprofen API market.
  • The acquisition by Solara Active Pharma Sciences Limited in 2018 of the Ibuprofen API assets of Strides and Sequent enabled the company to capture the portfolio of niche segments of the Ibuprofen API market.
  • The joint venture between Granules India Ltd (GIL) and Hubei Biocause Heilen Pharmaceutical Co. Ltd. have a production facility in Jingmen, China. In recent discussion, Granules India Ltd (GIL) is planning to part out from the joint venture.

Additionally, current acquisitions are focused on capacity expansion, and manufacturing capabilities of existing Ibuprofen API players in order to gain competitiveness and accelerate revenue growth in the market landscape.

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-11260

Why Future Market Insights?

  •   Comprehensive analysis on evolving purchase pattern across different geographies
  •   Detailed insights of market segments and sub-segments for historical as well as forecast period
  •   A competitive analysis of prominent players and emerging players in the keyword market
  •   Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Leave a comment

Your email address will not be published. Required fields are marked *